评估青年隐源性卒中患者复发性缺血性卒中的发生率:青年ESUS纵向队列研究
这项多中心纵向队列研究纳入41个中心、13个国家的535例50岁及以下ESUS患者,平均随访12个月,复发性缺血性卒中/死亡率为2.19/100患者年,缺血性卒中复发率为1.9/100患者年,新发房颤15例(2.8%;95%CI,1.6-4.6)。卒中或TIA史、糖尿病、冠心病史与复发相关。
要点
- 青年ESUS患者复发性缺血性卒中/死亡率为2.19/100患者年,缺血性卒中复发率为1.9/100患者年。
- 复发卒中中9例(64%)仍为ESUS,2例(14%)为心源性栓塞,3例(21%)为其他明确病因。
- 卒中或TIA史(HR 5.3)、糖尿病(HR 4.4)、冠心病史(HR 10)与复发缺血性卒中相关。
核心结论
- 在青年ESUS患者中,后续缺血性卒中的发生率相对较低,新发房颤的频率也较低。
- 大多数复发性卒中仍符合ESUS标准,提示需要未来研究以增进对该人群潜在卒中机制的理解。
研究设计与样本
- 多中心纵向队列研究,入组时间为2017年10月至2019年10月,平均随访12个月,至2020年10月结束。
- 研究纳入13个国家41个卒中研究中心的连续患者,年龄50岁及以下,诊断为ESUS。
- 筛查576例,535例入组(1例撤回知情同意,41例不符合条件,2例因其他原因排除),最终随访完成520例。
主要发现
- 参与者平均(SD)年龄为40.4(7.3)岁,297例(56%)为男性。
- 最常见的血管危险因素为吸烟(240例[45%])、高血压(118例[22%])和血脂异常(109例[20%])。
- 在接受经胸超声心动图联合发泡试验的参与者中,177例(50%)检出卵圆孔未闭(PFO)。
- 初始ESUS后,468例(88%)接受抗血小板治疗,52例(10%)接受抗凝治疗。
- 复发性缺血性卒中/死亡率为2.19/100患者年,缺血性卒中复发率为1.9/100患者年;复发卒中中9例(64%)为ESUS,2例(14%)为心源性栓塞,3例(21%)为其他明确病因;15例(2.8%;95%CI,1.6-4.6)检出房颤。
关键数值与推荐
- 多变量分析中,与复发性缺血性卒中相关的因素包括:卒中或短暂性脑缺血发作史(风险比5.3;95%CI,1.8-15)、糖尿病(风险比4.4;95%CI,1.5-13)、冠心病史(风险比10;95%CI,4.8-22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cryptogenic strokes constitute approximately 40% of ischemic strokes in young adults, and most meet criteria for the embolic stroke of undetermined source (ESUS). Two randomized clinical trials, NAVIGATE ESUS and RESPECT ESUS, showed a high rate of stroke recurrence in older adults with ESUS but the prognosis and prognostic factors among younger individuals with ESUS is uncertain. OBJECTIVE: To determine rates of and factors associated with recurrent ischemic stroke and death and new-onset atrial fibrillation (AF) among young adults. DESIGN, SETTING, AND PARTICIPANTS: This multicenter longitudinal cohort study with enrollment from October 2017 to October 2019 and a mean follow-up period of 12 months ending in October 2020 included 41 stroke research centers in 13 countries. Consecutive patients 50 years and younger with a diagnosis of ESUS were included. Of 576 screened, 535 participants were enrolled after 1 withdrew consent, 41 were found to be ineligible, and 2 were excluded for other reasons. The final follow-up visit was completed by 520 patients. MAIN OUTCOMES AND MEASURES: Recurrent ischemic stroke and/or death, recurrent ischemic stroke, and prevalence of patent foramen ovale (PFO). RESULTS: The mean (SD) age of participants was 40.4 (7.3) years, and 297 (56%) participants were male. The most frequent vascular risk factors were tobacco use (240 patients [45%]), hypertension (118 patients [22%]), and dyslipidemia (109 patients [20%]). PFO was detected in 177 participants (50%) who had transthoracic echocardiograms with bubble studies. Following initial ESUS, 468 participants (88%) were receiving antiplatelet therapy, and 52 (10%) received anticoagulation. The recurrent ischemic stroke and death rate was 2.19 per 100 patient-years, and the ischemic stroke recurrence rate was 1.9 per 100 patient-years. Of the recurrent strokes, 9 (64%) were ESUS, 2 (14%) were cardioembolic, and 3 (21%) were of other determined cause. AF was detected in 15 participants (2.8%; 95% CI, 1.6-4.6). In multivariate analysis, the following were associated with recurrent ischemic stroke: history of stroke or transient ischemic attack (hazard ratio, 5.3; 95% CI, 1.8-15), presence of diabetes (hazard ratio, 4.4; 95% CI, 1.5-13), and history of coronary artery disease (hazard ratio, 10; 95% CI, 4.8-22). CONCLUSIONS AND RELEVANCE: In this large cohort of young adult patients with ESUS, there was a relatively low rate of subsequent ischemic stroke and a low frequency of new-onset AF. Most recurrent strokes also met the criteria for ESUS, suggesting the need for future studies to improve our understanding of the underlying stroke mechanism in this population.
引用
- Perera KS, de Sa Boasquevisque D, Rao-Melacini P, et al. Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source: The Young ESUS Longitudinal Cohort Study. JAMA Neurol. 2022. PMID: 35285869. doi:10.1001/jamaneurol.2022.0048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。